Vascular cell adhesion molecule-1 (VCAM-1), an inducible cell-cell recognition protein on the endothelial cell surface (EC), has been associated with early stages of atherosclerosis. In view of the accelerated vascular disease observed in patients with diabetes, and the enhanced expression of VCAM-1 in diabetic rabbits, we examined whether irreversible advanced glycation endproducts (AGEs), could mediate VCAM-1 expression by interacting with their endothelial cell receptor (receptor for AGE, RAGE). Exposure of cultured human ECs to AGEs induced expression of VCAM-1, increased adhesivity of the monolayer for Molt-4 cells, and was associated with increased levels of VCAM-1 transcripts. The inhibitory effect of anti-RAGE IgG, a truncated form of the receptor (soluble RAGE) or N-acetylcysteine on VCAM-1 expression indicated that AGE-RAGE-induced oxidant stress was central to VCAM-1 induction. Electrophoretic mobility shift assays on nuclear extracts from AGE-treated ECs showed induction of specific DNA binding activity for NF-kB in the VCAM-1 promoter, which was blocked by anti-RAGE IgG or N-acetylcysteine. Soluble VCAM-1 antigen was elevated in human diabetic plasma. These data are consistent with the hypothesis that AGE-RAGE interaction induces expression of VCAM-1 which can prime diabetic vasculature for enhanced interaction with circulating monocytes. (J. Clin. Invest. 1995.96:1395-1403 
Introduction
Accelerated atherosclerosis and microvascular disease are the major vascular complications of diabetes, and constitute the principal cause of morbidity and mortality in this ubiquitous disorder (1) (2) . Many underlying factors could contribute to this outcome, including abnormalities in plasma lipoproteins, blood pressure, and renal function. A final common pathway in the development of vascular pathology is the expression of inducible adhesion molecules rendering the vasculature a selective target for circulating peripheral blood cells. In this context, vascular cell adhesion molecule-i (VCAM-1)' is of particular interest as its expression has been linked to the early phase of experimental hypercholesterolemia-induced atherosclerosis (3) (4) , and enhanced vascular VCAM-1 expression has been demonstrated in the vasculature of alloxan-treated diabetic rabbits (5) as well as in human atherosclerotic lesions (6) .
To identify a sustained stimulus for enhanced expression of VCAM-1 in diabetes, we have considered a potentially etiologic role for advanced glycation endproducts (AGEs). Exposure of proteins and lipids to aldoses results in nonenzymatic glycation; initially forming reversible early glycation products, Schiff bases, and Amadori products (7) , which, after complex molecular rearrangements, become irreversible AGEs (8) (9) (10) . The latter constitute a class of heterogeneous structures of yellowbrown color, characteristic fluorescence, which form crosslinks, generate reactive oxygen intermediates (ROIs), and interact with particular cellular receptors (8) (9) (10) (11) . The endothelial receptor for AGEs, termed RAGE, is a newly identified member of the immunoglobulin superfamily of cell surface molecules and has been shown to mediate interactions with these glycated proteins in vitro and in vivo ( 11 -14) . RAGE is expressed both in normal (15) and diabetic vasculature (A. M. Schmidt and D. Stem, unpublished observations).
Since AGEs are found in the plasma and accumulate in the vessel wall in diabetes, the potential role of interaction of AGEs with endothelial RAGE in induction of VCAM-1 expression was examined. Our data indicate that AGEs, either those prepared in vitro or isolated from patients with diabetes, led to VCAM-1 expression in cultured ECs by a mechanism involving AGE binding to RAGE likely as a consequence of induction of cellular oxidant stress and activation of the transcription factor NF-kB. Infusion of AGEs into mice also enhanced vascular VCAM-1 expression, and soluble VCAM-1 antigen was ele-vated in plasma of patients with diabetes, suggesting increased VCAM-1 production. These data support the concept of a role for AGEs in enhanced expression of VCAM-1 in diabetes, and suggest that this could provide a mechanism for targeting mononuclear phagocytes (MPs) to diabetic vasculature.
Methods
Endothelial cell culture and RAGE blocking reagents. Human ECs were prepared from umbilical cords, grown in culture as described (16, 17) , and experiments utilized confluent cultures (passages 1-3) grown in Medium 199 supplemented with fetal bovine serum (15%; Gemini, Calabasas, CA), human serum (5%; Gemini), endothelial cell growth supplement (Boehringer Mannheim, Indianapolis, IN), heparin (90 0g/ ml; Sigma Chemical Co., St. Louis, MO) and antibiotics. In most experiments, human umbilical vein endothelial cells (ECs) were used, but where specifically indicated, certain experiments were performed with human aortic endothelial cells (Clonetics, San Diego, CA). Confluent cultures of human aortic endothelial cells were used for experiments at passages 4-6. RAGE is present on the surface of both human umbilical vein and human aortic endothelial cells by immunohistochemistry using previously published methods (15, data not shown). Blockade of EC RAGE used soluble(s) bovine RAGE and monospecific antibody to sRAGE. Bovine RAGE was purified to homogeneity from bovine lung acetone powder (Sigma Chemical Co.) by the methods previously described (12) . This material represents the amino-terminal two-thirds of the molecule based on analysis of tryptic peptides and is called soluble RAGE or sRAGE. Purified bovine RAGE was used to immunize rabbits, according to previously described methods (18) , IgG was purified by affinity chromatography with immobilized protein A, and nonimmune rabbit IgG was similarly prepared. Immunoblotting studies showed that anti-RAGE IgG was monospecific; it bound only RAGE and binding was blocked completely by pre-adsorption with purified RAGE. F(ab' )2 was prepared from IgG with a kit from Pierce (Rockville, IL) according to the manufacturer's instructions. The final F(ab')2, which was homogeneous on SDS PAGE, was then dialyzed extensively versus phosphate-buffered saline.
Preparation ofglycatedproteins and antibodies. Bovine serum albumin (fatty acid free; Sigma Chemical Co.) was glycated by incubation with glucose (0.5 M) at 37°C for 4 wk. Glycated proteins were characterized based on fluorescence, binding to cultured ECs and to purified RAGE (18) . SDS-PAGE showed a single major band corresponding to 69 kD, and the isoelectric point was largely unchanged (a shift of < 0.1-0.3 pH units toward acidity was variably noted; characterization of these glycated albumin preparations has previously been described in detail [18 ] ). Nonglycated albumin was treated identically as glycated albumin (i.e., incubation at 37°C for 4 wk) except that no glucose was present in the reaction mixture. AGEs were immunoisolated from diabetic serum using affinity-purified anti-AGE IgG, prepared and characterized as described previously (18, 19) . This antibody selectively reacts with AGE-modified forms of proteins, but not native polypeptides, nor early glycation adducts, or other modifications (formylation, maleylation, acetylation, or copper oxidation) ( 19) . Anti-AGE IgG was immobilized on Affi-Gel 10 (BioRad, Hercules, CA) according to the manufacturer's instructions and diabetic serum was applied. The material that did not adhere to this column, defined as AGE-depleted serum, was subsequently negative for AGE-immunoreactive material as determined by AGE ELISA which used the above affinity-purified anti-AGE IgG (18, 19) . After collecting the AGE-depleted material, the column was washed extensively with neutral buffer and eluted with high salt (NaCl, 2 M) as described ( 18) . Serum Marui et al. (20) . ECs, grown to confluence in 0.38 cm2 wells, were washed twice in Medium 199 containing fetal bovine serum (1%) and then exposed to either AGE albumin or native albumin for the indicated time at 37TC. Where indicated, ECs were pre-treated with one of the following: N-acetylcysteine (NAC; 30 mM for 60 min), cycloheximide (50 ,g/ml for 60 min), anti-RAGE F(ab')2 (2 pg/ml for 3 h), nonimmune F(ab')2 (2 ,jg/ml for 3 h), or anti-VCAM-l F(ab')2 (10 jig/ml or 0.1 jig/ml for 30 min). F(ab')2 fragments prepared from murine monoclonal antibody to VCAM-1 (2G7) were (18, 19) .
Northern blotting. RNA prepared from cultured ECs (108 cells) using the guanidinium thiocyanate procedure (23) was applied to agarose-formaldehyde gels (0.8%; 30 ,g), and transferred to nylon filters.
Filters were prehybridized for 1 h at 680C with QUIK Hyb buffer (Stratagene, La Jolla, CA) and hybridized in QUIK Hyb buffer for 3 h at 680C in the presence of 32P-labeled full-length human VCAM-1 cDNA (24) labeled by the random primer procedure. Filters were then washed with SSC (2x) containing SDS (0.1%) twice for 15 min each at room temperature, washed again with SSC (0.1x) containing SDS (0.1%) for 30 min at 550C, dried and subjected to autoradiography. To assess RNA loading, filters were also hybridized with random primer labeled 32P-cDNA for glyceraldehyde phosphate dehydrogenase (GAPDH) using the same washing and hybridization procedure.
Nuclear run-on transcription assay. Nuclear run-on transcription assay was performed using a modification of the methods as described by Santisteban et al. (25) . ECs were incubated with AGE albumin (100 sg/ml) or native albumin (100 ug/ml) for 6 h at 37TC. Monolayers were then washed twice with cold phosphate-buffered saline, scraped, and cell pellets prepared. Pellets were then resuspended in 10 ml of lysis buffer containing Tris (0.01 M, pH 7.4), NaCl (10 mM), MgCl2 (3 mM), Nonidet P40 (0.5% [vol/vol]), leupeptin (50 sg/ml), dithiothreitol (1 mM), phenylmethylsulfonyl fluoride (0.5 mM), and aprotinin (100 sg/ml), incubated for 15 min on ice, and centrifuged at 500 g for 5 min at 40C. The nuclear pellets were washed once with lysis buffer as above (4 ml) and centrifuged at 500 g for 5 min at 4TC. Supernatants were discarded and nuclei resuspended in 0.2 ml reaction buffer containing Tris (10 mM, pH 8.0), MgCl2 (5 mM), KCl (300 mM), dithiothreitol (1 mM), ATP (0.5 mM), CTP (0.5 mM), GTP (0.5 mM), and 200 microcurie of [a-32P]UTP (3, (Fig. 1 A) and gradually fell to the baseline by 12 h (data not shown). AGE-enhanced binding of Molt-4 cells to endothelium was prevented by blocking with F(ab')2 against VCAM-1, suggesting a central role for VCAM-1 as the EC adherence molecule mediating this interaction (Fig. 1 B) . De novo endothelial protein synthesis was required to support Molt-4 binding, as preincubation of endothelium with cycloheximide was inhibitory (Fig. 1 B) . Molt-4 binding to AGE-treated ECs was not due to passive adsorption of the glycated protein to the endothelial surface because affinity-purified antibody to AGEs, which prevents their cellular interactions (18, 19) , had no effect when added during the adherence assay (data not shown).
In parallel with increased VCAM-1 -dependent binding of Molt-4 cells to AGE-treated endothelium, expression of VCAM-1 antigen by ECs was enhanced as measured by ELISA ( Fig. 2 A) ; this occurred in a time-dependent manner similar to that observed for Molt-4 binding to AGE-treated endothelium (data not shown). Enhancement of cellular VCAM-I expression by AGEs was prevented by addition of cycloheximide (Fig.  2 A) , consistent with results of cell adherence experiments (Fig.  1 B) . AGEs obtained from diabetic serum (18) also enhanced EC expression of VCAM-1 (Fig. 2 A) , indicating that AGEadducts generated in vivo had similar properties, with respect to endothelial VCAM-I expression, compared to AGE albumin prepared in vitro. In contrast, AGE-depleted serum was without effect (Fig. 2 A) . The effect of AGEs on VCAM-I expression was selective, as there was no change in EC levels of ICAM-1 as measured by ELISA after treatment with AGE albumin (Fig. 2 B) , whereas tumor necrosis factor-a, added as a positive control, significantly increased ICAM-1 expression (27) . Human aortic vein endothelial cells were also tested for their response to AGEs since they more closely approximate the endothelial cells likely to be relevantly affected in in vivo models of atherosclerosis. When human aortic endothelial cells were exposed to AGE albumin, expression of cellular VCAM-1 antigen was increased as measured by ELISA (Fig. 2 C) whereas native albumin was without effect (Fig. 2 C) .
Consistent with possible AGE-induced de novo synthesis of VCAM-1, levels of VCAM-1 mRNA were elevated in ECs exposed to AGE albumin, whereas transcripts for GAPDH were unchanged (Fig. 2 D) . Nuclear run-on transcription assay indicated that this was due to increased transcription of mRNA for VCAM-1 in AGE-treated ECs (Fig. 2 E) .
Mechanisms underlying AGE-induced EC expression of (Fig.  3 A) and anti-RAGE IgG blocked the increase in VCAM-1 antigen completely (Fig. 3 B) , whereas nonimmune reagents had no effect (Fig. 3, A and B) . sRAGE had a similar, though even more complete (> 95%) inhibitory effect on the binding of Molt-4 cells to AGE-treated ECs and their expression of VCAM-1 (Fig. 3, A and B) . These data indicated that AGE-RAGE interaction had a central role in AGE induction of endothelial VCAM-1. AGEs tethered to cell surface RAGE induce cellular oxidant stress; this assertion is based on several lines of evidence, including generation of thiobarbituric acid-reactive substances, expression of heme oxygenase type I mRNA, and activation of the transcription factor NF-kB ( 19) . NF-kB sites in the VCAM-1 promoter have been shown to participate in regulation of VCAM-1 expression in response to cytokines, mediated, at least in part, by an oxidant mechanism impacting on activation of NF-kB (20, 24, 28) . These data led us to examine if AGEinduced cellular oxidant stress was involved in up-regulating VCAM-1 expression. Pretreatment of endothelium with the antioxidant N-acetylcysteine inhibited AGE-enhanced Molt-4 binding (Fig. 3 A) as well as enhanced expression of VCAM-1 antigen (Fig. 3 B) . In addition, AGE binding to endothelial RAGE triggered events resulting in expression of DNA binding activity for the NF-kB site in the VCAM-1 promoter. Activation of NF-kB, by incubating the ECs with TNF-a, served as a positive control in this experiment (Fig. 3 C, lane 1) . After exposure of ECs to AGE albumin, EMSA demonstrated a gel shift band (Fig. 3 C, lanes 3, 6, and 10 ) not observed with cultures exposed to native albumin (Fig. 3 C, lane 2) . AGEinduced DNA binding activity was sequence specific, as its appearance was blocked by excess unlabelled NF-kB probe, but was not affected by a mutationally inactivated NF-kB probe (Fig. 3 C, lanes 4 and 5, respectively) . DNA binding activity was probably dependent on p50 and p65 proteins of the NF-kB family in the nucleus, as indicated by the distinct retardation patterns of AGE-induced gel shift bands in the presence of antip65 IgG (Fig. 3 C, lane 7) , anti-p5O IgG (Fig. 3 C, lane 8) or in the presence of both antibodies (Fig. 3 C, lane 9) , suggesting the involvement of both the p50 and p65 proteins of the NFkB family. The same concentration of nonimmune IgG was without effect (data not shown). NF-kB activation was largely inhibited by the higher concentration of anti-RAGE IgG, 70 pg/ml (Fig. 3 C, lane 11) whereas a lower concentration of anti-RAGE IgG, 0.7 a.tg/ml had no effect (Fig. 3 C, lane 12) . In contrast, nonimmune IgG did not alter intensity of the AGEinduced gel shift band (Fig. 3 C, lane 13) . NF-kB activation by AGE albumin was also inhibited by addition of N-acetylcysteine (Fig. 3 C, lane 14) . These data indicate that AGE binding to endothelial RAGE activates nuclear binding activity for the VCAM-1 NF-kB site, likely via an oxidant mechanism. Consistent with these data, elevated levels of VCAM-1 transcripts in AGE-treated ECs were blocked in the presence of anti-RAGE IgG, but not with nonimmune IgG (Fig. 3 D, lanes 2 and 3,  respectively) , and by N-acetylcysteine (data not shown).
RAGE comprising the extracellular domain (11-13). Pre-incubation of ECs with anti-RAGE F(ab ' )2 largely prevented AGEmediated increased endothelial adherence of Molt-4 cells
Infusion of AGEs induces VCAM-J in mice and patients with diabetes display increased expression of soluble VCAM-1. In view of the association of AGEs and oxidant stress with diabetes (8), we considered whether induction of VCAM-1 might occur in diabetic vasculature. To approach this question, 1398 Schmidt et al. TsAf (I &~s +sF-sp AGE albumin. The mean±SEM of at least triplicate determinations is shown. ** above AGE albumin and patient AGEs denotes P < 0.001 compared to native albumin using the student's unpaired t test, and ** above CHX-AGE albumin denotes P < 0.001 compared with treatment with AGE albumin alone using the student's unpaired t test. (B) ECs (human umbilical vein) were incubated for 6 h at 37TC with AGE albumin (100 jig/ml) or native albumin (100 jig/ml) and cellular ELISA for ICAM-1 antigen was performed. As indicated, TNF (10 nM) was incubated for 6 h at 37TC with ECs as a positive control. The mean±SEM of at least triplicate determinations is shown. * denotes P < 0.01 compared with native albumin alone using the student's unpaired t test. (C) Human aortic endothelial cells were incubated for 6 h with AGE albumin (100 jg/ml) or native, nonglycated albumin at 37TC, and then cell-associated ELISA for VCAM-I antigen was performed. The mean±SEM of at least triplicate determinations is shown. * * above AGE albumin indicates P < 0.001 compared to native albumin using the student's unpaired t test. (D) Northern analysis of EC RNA for VCAM-1 transcripts: effect of AGE albumin. ECs were incubated with TNF-a (10 nM) (lane 1) or native nonglycated albumin (100 pHg/ml) (lane 2) or AGE albumin (100 jig/ml) (lane 3) as indicated for 6 h at 37TC, RNA was harvested, subjected to electrophoresis, blotted onto nitrocellulose and hybridization with 32P-labeled cDNA probes for VCAM-1 or GAPDH performed as indicated. (E) Nuclear run-on transcription assay: ECs were treated with AGE albumin (100 jig/ml) or native albumin (100 jig/ml) for 6 h at 37TC, nuclei isolated and 32P-labeled nuclear run on products hybridized to denatured human VCAM-1 gene DNA or ,/-actin gene DNA slot-blotted on nylon filters, as described above.
AGE albumin was infused into normal mice and expression of VCAM-1 in the vasculature was assessed. After administration of AGE albumin, VCAM-1 was identified in murine vasculature by immunostaining (Fig. 4 B) , but was absent in animals infused with native albumin (Fig. 4 A) .
These data led us to inquire whether patients with diabetes might also exhibit increased expression of VCAM-1. In pilot studies, incubation of AGE albumin with ECs not only led to increased cell-associated VCAM-1 (Fig. 2 A) , but also to increased soluble(s) VCAM-1 in culture supernatants based on ELISA ( Fig. 4 C) ; elaboration of sVCAM-1 occurred in a timedependent manner parallelling expression of cellular VCAM (data not shown). Of note, pilot studies revealed that EC supernatants containing sVCAM-1 did not antagonize binding of Molt-4 cells to stimulated ECs expressing VCAM-1 (data not shown). These data suggested that sVCAM-1 might serve as a marker for AGE-induced (and probably the capacity of other mediators to induce) VCAM-1 expression. sVCAM-l antigen was measured in patients with a spectrum of diabetic complications at different stages in the severity of their vascular disease (Fig. 4 D) . Only patients with diminished glomerular filtration rate were excluded, as sVCAM-1 levels have been shown to be elevated with renal insufficiency (29) . Patients with diabetes (n = 18) displayed sVCAM-1 levels (mean, 1,115 ng/ml) 1.8-fold higher than that observed in age-matched nondiabetic controls (mean, 632 ng/ml) (n = 20; P < 0.001 using the student's unpaired t test). Consistent with these data, diabetic patients demonstrated higher circulating levels of plasma AGEs as measured by ELISA (244 ng/ml AGE albumin equivalents) than age-matched controls (157 ng/mi AGE albumin equivalents, P < 0.001 using the student's unpaired t test).
Discussion
Our results indicate that AGEs, aldose-modified proteins present within the intravascular space and which accumulate in the vessel wall and other tissues especially in diabetes (7) (8) (9) (10) , interact with endothelium to induce VCAM-1, an adhesion molecule for MPs associated with development of atherosclerosis (3) (4) (5) (6) . These data add to a growing body of evidence concernEndothelium, Receptors, and Glycation 1399 (30) ; changes of migration when a deposit of immobilized AGEs is encounin cell surface coagulant properties with induction of low levels tered (18, 31, 32) . Expression of VCAM-1 by ECs in response of tissue factor procoagulant activity (30) ; and receptor-medito AGE albumin probably underlies the enhanced monocyte ated transcytosis and delivery of the glycated ligand to the binding followed by transmigration through EC monolayers subendothelium (14) where it permits interaction with smooth grown on filters with AGEs in the lower compartment ( 18, 31 Control Plasma Diabe have a more sustained effect on EC expression of VCAM-1 and/or could magnify effects of other stimuli which modulate endothelial VCAM-1 production, such as cytokines (27) . Thus, measurement of circulating (plasma) AGE levels may only be partially relevant given the likely diffuse distribution of pathogenic irreversibly-glycated proteins in the vasculature, only some of which may be readily amenable to isolation and analysis pre-mortem. Although AGEs comprise a class of heterogeneous structures, their interactions with endothelium appear to be mediated mostly via RAGE (11) (12) . In the current studies, either blocking antibody/F(ab')2 or sRAGE inhibited induction of VCAM-1 at the same concentrations that blocked binding of AGE albumin to the EC surface. Interaction of AGE albumin with MPs, as well as their interaction with other AGE-modified proteins (34) , has been shown similarly to involve RAGE, suggesting that this receptor is a major site for cell surface AGE-mediated events although other AGE cellular binding sites may also be present (35, 36) . VCAM-1 expression appears to be induced by generation of cellular oxidant stress consequent on cell surface AGE-RAGE interaction. This could arise from ROls produced by the glycated proteins themselves (8, (37) (38) (39) (40) and/or receptor-mediated triggering of signal transduction mechanisms leading to low levels of oxygen-free radical production (20, 24, (41) (42) (43) The observation that the AGE-RAGE interaction induces cell-associated VCAM-1, and also releases sVCAM-l antigen into culture supernatants, suggests a means of monitoring this event in vivo. Furthermore, increased levels of sVCAM-1 were observed in diabetic patients compared with a range of normal controls. Although the functional significance of sVCAM-l is at present unclear (pilot studies have shown lack of antagonism of Molt-4 binding to EC surface VCAM-1), sVCAM-1 could serve as a marker of vascular perturbation in diabetes. Since endothelial expression of VCAM-1 occurs in response to diverse stimuli, including cytokines (27) , and could result from the oxidant stress consequent on hyperglycemia itself (44), Endothelium, Receptors, and Glycation 1401 ) _ plasma VCAM-1 levels are likely to reflect the complexity of events which occur within the vasculature in vivo. Even with these diverse stimuli for induction of VCAM-1 in diabetes, we hypothesize that serial sVCAM-1 levels could be of benefit in identifying patients at high risk for the development of clinically apparent vascular complications (as a result of EC perturbation due to AGEs or other agents) and might provide a surrogate marker for assessment of therapy designed to attenuate the progression of vascular disease.
Taken together with our recent demonstration that AGEs induce expression by smooth muscle cells of the chemotactic polypeptide JE/MCP-1 (45) , these data suggest a pathway through which AGEs attract monocytes to bind to the vessel surface, followed by their migration into the vessel wall and subsequent stimulation with production of mediators potentially contributing to the development of vascular lesions. The recent observation of increased VCAM-1 expression in diabetic rabbits (5) and our finding of elevated sVCAM-1 levels in diabetic patient plasma suggests that this cell adherence molecule might have a important role in the pathogenesis of diabetic vascular disease.
